SYNTHESIS AND ANTITUMOR EVALUATIONS OF SYMMETRICALLY AND UNSYMMETRICALLY SUBSTITUTED 1,4-BIS[(AMINOALKYL)AMINO]ANTHRACENE-9,10-DIONES AND 1,4-BIS[(AMINOALKYL)AMINO]-5,8-DIHYDROXYANTHRACENE-9,10-DIONES

被引:70
作者
KRAPCHO, AP
GETAHUN, Z
AVERY, KL
VARGAS, KJ
HACKER, MP
SPINELLI, S
PEZZONI, G
MANZOTTI, C
机构
[1] UNIV VERMONT, DEPT PHARMACOL, BURLINGTON, VT 05405 USA
[2] BOEHRINGER MANNHEIM ITALIA SPA, MONZA, ITALY
关键词
D O I
10.1021/jm00112a009
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
The ipso bis displacements of fluoride from 1,4-difluoroanthracene-9,10-dione (3) and 1,4-difluoro-5,8-dihydroxy-anthracene-9,10-dione (4) by excess of a diamine (or a monoamine) in pyridine at room temperature lead to the symmetrically substituted 1,4-bis-substituted analogues 5 and 6, respectively. The ipso monodisplacements of fluoride from 3 and 4 can be accomplished by treatment with less than 1 molar equiv of a diamine (or a monoamine) to yield 7 and 8, respectively. Treatment of 7 or 8 with a different diamine leads to the unsymmetrically substituted 1,4-bis[(aminoalkyl)amino]anthracene-9,10-diones 9 and 10, respectively. Many of the synthetic unsymmetrical analogues have been evaluated for their antitumor activity against L1210 in vitro and in vivo. Cross resistance of analogue 10a with mitoxantrone (2) and doxorubicin was evaluated against MDR lines in vitro against human colon carcinoma LOVO and its subline resistant to DOXO (LOVO/DOXO). Potential mechanisms for the observed cytotoxicity are presented and discussed.
引用
收藏
页码:2373 / 2380
页数:8
相关论文
共 79 条
[1]  
BACKMANN E, 1987, CANCER TREAT REP, V71, P361
[2]   DESIGN OF DNA INTERCALATORS TO OVERCOME TOPOISOMERASE II-MEDIATED MULTIDRUG RESISTANCE [J].
BAGULEY, BC ;
HOLDAWAY, KM ;
FRAY, LM .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1990, 82 (05) :398-402
[3]   DESIGN OF ANTICANCER DRUGS USING MODELING TECHNIQUES [J].
BALAJI, VN ;
DIXON, JS ;
SMITH, DH ;
VENKATARAGHAVAN, R ;
MURDOCK, KC .
ANNALS OF THE NEW YORK ACADEMY OF SCIENCES, 1985, 439 (MAR) :140-161
[4]  
BASRA J, 1985, ANTI-CANCER DRUG DES, V1, P45
[5]  
BOWDEN GT, 1985, CANCER RES, V45, P4915
[6]  
BURKE TG, 1987, CANCER BIOCHEM BIOPH, V9, P245
[7]   INFLUENCE OF MITOXANTRONE ON NUCLEOLAR FUNCTION IN MDA-MB-231 HUMAN-BREAST TUMOR-CELL LINE [J].
CHEGINI, N ;
SAFA, AR .
CANCER LETTERS, 1987, 37 (03) :327-336
[8]  
Chen G.L, 1986, ANNU REP MED CHEM, V21, P257, DOI [10.1016/S0065-7743(08)61134-3, DOI 10.1016/S0065-7743(08)61134-3]
[9]   A THEORETICAL INVESTIGATION ON THE SEQUENCE SELECTIVE BINDING OF MITOXANTRONE TO DOUBLE-STRANDED TETRANUCLEOTIDES [J].
CHEN, KX ;
GRESH, N ;
PULLMAN, B .
NUCLEIC ACIDS RESEARCH, 1986, 14 (09) :3799-3812
[10]   THE DESIGN, SYNTHESIS AND DEVELOPMENT OF A NEW CLASS OF POTENT ANTINEOPLASTIC ANTHRAQUINONES [J].
CHENG, CC ;
ZEECHENG, RKY .
PROGRESS IN MEDICINAL CHEMISTRY, 1983, 20 :83-118